Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
@article{ATM79484, author = {Yafei Shi and Wei Chen and Yujun Zhang and Mingming Bo and Chunyu Li and Mingyu Zhang and Guohui Li}, title = {Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China}, journal = {Annals of Translational Medicine}, volume = {9}, number = {18}, year = {2021}, keywords = {}, abstract = {}, issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/79484} }